Treatment of Non-Neurogenic Overactive Bladder – American Urological Association and Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction Guideline Overview
Authors:
Z. Ficko; E. A. Gormley
Authors‘ workplace:
USA
; Dartmouth Hitchcock Medical Center
; Lebanon, New Hampshire
; Urology Section
Published in:
Urol List 2015; 13(3): 6-13
Overview
This manuscript reviews the treatment options for non-neurogenic overactive bladder, based on the updated 2014 American Urological Association a Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction guideline. The guideline is based on 223 English language articles published between 1966 and 2014, and discusses the sequence in which therapies should be offered. Behavioral therapies are first-line treatments, anti-muscarinics and β3-adrenergic agonists are second-line treatments, onabotulinumtoxin A injections, peripheral tibial nerve stimulators and sacral neuromodulation are third-line treatments, and indwelling catheters, augmentation cystoplasty and urinary diversion are only offered as a last resort in very selective cases.
Key Words:
overactive bladder urinary incontinence urinary urgency urinary frequency nocturia
Sources
1. Haylen BT, de Ridder D, Freeman RM et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn 2010; 29(1): 4–20. doi: 10.1002/nau.20798.
2. Gormley EA, Lightner DJ, Burgio KL et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. J Urol 2012; 188(6): 2455–2463. doi: 10.1016/j.juro.2012.09.079.
3. Fitzgerald MP, Brubaker L. Variability of 24-hour voiding diary variables among asymptomatic women. J Urol 2003; 169(1): 207–209.
4. Gormley EA, Lightner DJ, Faraday M et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment. J Urol 2015; 193(5): 1572–1580. doi: 10.1016/j.juro.2015.01.087.
5. Fantl JA, Wyman JF, McClish DK et al. Efficacy of bladder training in older women with urinary incontinence. JAMA 1991; 265(5): 609–613.
6. Jarvis GJ. A controlled trial of bladder drill and drug therapy in the management of detrusor instability. BJU Int 1981; 53(6): 565–566.
7. Burgio KL, Locher JL, Goode PS et al. Behavioral vs drug treatment for urge urinary incontinence in older women: a randomized controlled trial. JAMA 1998; 280(23): 1995–2000.
8. Burgio KL, Goode PS, Johnson TM et al. Behavioral versus drug treatment for overactive bladder in men: the male overactive bladder treatment in veterans (MOTIVE) trial. J Am Geriatr Soc 2011; 59(12): 2209–2216. doi: 10.1111/j.1532-5415.2011.03724.x.
9. Goode PS, Burgio KL, Locher JL et al. Urodynamic changes associated with behavioral and drug treatment of urge incontinence in older women. J Am Geriatr Soc 2002; 50(5): 808–816.
10. Kaya S, Akbayrak T, Beksac S. Comparison of different treatment protocols in the treatment of idiopathic detrusor overactivity: a randomized controlled trial. Clin Rehabil 2011; 25(4): 327–338. doi: 10.1177/0269215510385481.
11. Subak LL, Wing R, West DS et al. Weight loss to treat urinary incontinence in overweight and obese women. N Engl J Med 2009; 360(5): 481–490. doi: 10.1056/NEJMoa0806375.
12. Hashim H, Abrams P. How should patients with an overactive bladder manipulate their fluid intake? BJU Int 2008; 102(1): 62–66. doi: 10.1111/j.1464-410X.2008.07463.x.
13. Bryant CM, Dowell CJ, Fairbrother G. Caffeine reduction education to improve urinary symptoms. Br J Nurs 2002; 11(8): 560–565.
14. Burgio KL, Goode PS, Locher JL et al. Behavioral training with and without biofeedback in the treatment of urge incontinence in older women: a randomized controlled trial. JAMA 2002; 288(18): 2293–2299.
15. Wang AC, Wang YY, Chen MC. Single-blind, randomized trial of pelvic floor muscle training, biofeedback-assisted pelvic floor muscle training, and electrical stimulation in the management of overactive bladder. Urology 2004; 63(1): 61–66.
16. Cartwright R, Srikrishna S, Cardozo L et al. Patient-selected goals in overactive bladder: a placebo controlled randomized double-bind trial of transdermal oxybutynin for the treatment of urgency and urgent incontinence. BJU Int 2010; 107(1): 70–76. doi: 10.1111/j.1464-410X.2010.09591.x.
17. Nitti, VW, Khullar V, van Kerrebroeck P et al. Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomized, double-blind, placebo-controlled, phase III studies. Int J Clin Pract 2013; 67(7): 619–632. doi: 10.1111/ijcp.12194.
18. Herschorn S, Barkin J, Castro-Diaz D et al. A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the beta(3) adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder. Urology 2013; 82(2): 313–320. doi: 10.1016/j.urology.2013.02.077.
19. Lipton RB, Kolodner K, Wesnes K. Assessment of cognitive function of the elderly population: effects of darifenacin. J Urol 2005; 173(2): 493–498.
20. Kay G, Crook T, Rekeda L et al. Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects. Eur Urol 2006; 50(2): 317–326.
21. Cui Y, Wang L, Liu L et al. Botulinum toxin-A injections for idiopathic overactive bladder: a systematic review and meta-analysis. Urol Int 2013; 91(4): 429–438. doi: 10.1159/000351037.
22. Dmochowski R, Chapple C, Nitti V et al. Efficacy and safety of onabotulinumtoxin A for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial. J Urol 2010; 184(6): 2416–2422. doi: 10.1016/j.juro.2010.08.021.
23. Kuo, HC. Comparison of effectiveness of detrusor, suburothelial and bladder base injections of botulinum toxin A for idiopathic detrusor overactivity. J Urol 2007; 178(1): 1359–1363.
24. Brubaker L, Richter HE, Visco A et al. Refractory idiopathic urge urinary incontinence and botulinum A injection. J Urol 2008; 180(1): 217–222. doi: 10.1016/j.juro.2008.03.028.
25. Sahai A, Khan MS, Dasgupta P. Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial. J Urol 2007; 177(6): 2231–2236.
26. Jeffery S, Fynes M, Lee F et al. Efficacy and complications of intradetrusor injection with botulinum toxin A in patients with refractory idiopathic detrusor overactivity. BJU Intl 2007; 100(6): 1302–1306.
27. Kessler TM, Danuser H, Schumacher M et al. Botulinum A toxin injections into the detrusor: an effective treatment in idiopathic and neurogenic detrusor overactivity? Neurourol Urodyn 2005; 24(3): 231–236.
28. Kessler TM, Khan S, Panicker J et al. Clean intermittent self-catheterization after botulinum neurotoxin type A injections: short-term effect on quality of life. Obstet Gynecol 2009; 113(5): 1046–1051. doi: 10.1097/AOG.0b013e3181a1f5ea.
29. Khan S, Kessler TM, Apostolidis A et al. What a patient with refractory idiopathic detrusor overactivity should know about botulinum neurotoxin type A injection. J Urol 2009; 181(4): 1773–1778. doi: 10.1016/j.juro.2008.11.110.
30. Wang CC, Liao CH, Kuo HC. Diabetes mellitus does not affect the efficacy and safety of intravesical onabotulinumtoxin A injection in patients with refractory detrusor overactivity. Neurourol Urodyn 2014; 33(8): 1235–1239. doi: 10.1002/nau.22494.
31. Liao CH, Kuo HC. Increased risk of large post-void residual urine and decreased long-term success rate after intravesical onabotulinumtoxin A injection for refractory idiopathic detrusor overactivity. J Urol 2013; 189(5): 1804–1810. doi: 10.1016/j.juro.2012.11.089.
32. Dowson C, Watkins J, Khan MS et al. Repeated botulinum toxin type A injections for refractory overactive bladder: medium-term outcomes, safety profile, and discontinuation rates. Eur Urol 2012; 61(4): 834–839. doi: 10.1016/j.eururo.2011.12.011.
33. Veeratterapillay R, Harding C, Teo L et al. Discontinuation rates and inter-injection interval for repeated intravesical botulinum toxin type A injections for detrusor overactivity. Int J Urol 2014; 21(2): 175–178. doi: 10.1111/iju.12205.
34. Mohee A, Khan A, Harris N et al. Long-term outcome of the use of intravesical botulinum toxin for the treatment of overactive bladder (OAB). BJU Int 2013; 111(1): 8. doi: 10.1111/j.1464-410X.2012.11285.x.
35. Hegele A, Frohme C, Varga Z et al. Antibodies after botulinum toxin A injection into musculus detrusor vesicae: incidence and clinical relevance. Urol Int 2011; 87(4): 439–444. doi: 10.1159/000332194.
36. Klingler HC, Pycha A, Schmidbauer J et al. Use of peripheral neuromodulation of the S3 region for treatment of detrusor overactivity: a urodynamic--based study. Urology 2000; 56(5): 766–771.
37. MacDiarmid SA, Peters KM, Shobeiri SA et al. Long-term durability of percutaneous tibial nerve stimulation for the treatment of overactive bladder. J Urol 2010; 183(1): 234–240. doi: 10.1016/j.juro.2009.08.160.
38. Peters KM, Carrico DJ, Perez-Marrero RA et al. Randomized trial of percutaneous tibial nerve stimulation versus Sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT trial. J Urol 2010; 183(4): 1438–1443. doi: 10.1016/j.juro.2009.12.036.
39. Marchal C, Herrera B, Antuna, F et al. Percutaneous tibial nerve stimulation in treatment of overactive bladder: when should retreatment be started? Urology 2011; 78(5): 1046–1050. doi: 10.1016/j.urology.2011.07.1394.
40. Peters KM, Shen L, McGuire M. Effect of sacral neuromodulation rate on overactive bladder symptoms: a randomized crossover feasibility study. LUTS 2013; 5(3): 129–133.
41. Yoong W, Shah P, Dadswell R et al. Sustained effectiveness of percutaneous tibial nerve stimulation for overactive bladder syndrome: 2-year follow-up of positive responders. Int Urogynecol J 2013; 24(5): 795–799. doi: 10.1007/s00192-012-1936-3.
42. Peters KM, MacDiarmid SA, Wooldridge LS et al. Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the overactive bladder innovative therapy trial. J Urol 2009; 182(3): 1055–1061. doi: 10.1016/j.juro.2009.05.045.
43. Sancaktar M, Ceyhan ST, Akyol I et al. The outcome of adding peripheral neuromodulation (Stoller afferent neuro-stimulation) to anti-muscarinic therapy in women with severe overactive bladder. Gynecol Endocrinol 2010; 26(10): 729–732. doi: 10.3109/09513591003649815.
44. Souto SC, Reis LO, Palma T et al. Prospective and randomized comparison of electrical stimulation of the posterior tibial nerve versus oxybutynin versus their combination for treatment of women with overactive bladder syndrome. World J Urol 2013; 32(1): 179–184. doi: 10.1007/s00345-013-1112-5.
45. Gaziev G, Topazio L, Iacovelli V et al. Percutaneous Tibial Nerve Stimulation (PTNS) efficacy in the treatment of lower urinary tract dysfunctions: a systematic review. BMC Urol 2013; 13: 61–72. doi: 10.1186/1471-2490-13-61.
46. Moossdorff-Steinhauser HF, Berghmans B. Effects of percutaneous tibial nerve stimulation on adult patients with overactive bladder syndrome: a systematic review. Neurourol Urodyn 2013: 32(3): 206–214. doi: 10.1002/nau.22296.
47. Siegel S, Noblett K, Mangel J et al. Results of a prospective, randomized, multicenter study evaluating sacral neuromodulation with InterStim therapy compared to standard medical therapy at 6-months in subjects with mild symptoms of overactive bladder. Neurourol Urodyn 2015; 34(3): 224–230. doi: 10.1002/nau.22544.
48. Angioli R, Montera R, Plotti F et al. Success rates, quality of life, and feasibility of sacral nerve stimulation in elderly patients: 1-year follow-up. Int Urogynecol J 2013; 24(5): 789–794. doi: 10.1007/s00192-012-1928-3.
49. Faucheron JL, Chodez M, Boillot B. Neuromodulation for fecal and urinary incontinence: functional results in 57 consecutive patients from a single institution. Dis Colon Rectum 2012; 55(12): 1278–1283. doi: 10.1097/DCR.0b013e31826c7789.
50. Smits MA, Oerlemans D, Marcelissen TA et al. Sacral neuromodulation in patients with idiopathic overactive bladder after initial botulinum toxin therapy. J Urol 2013; 190(6): 2148–2152. doi: 10.1016/j.juro.2013.07.017.
51. Leong RK, Marcelissen TA, Nieman FH et al. Satisfaction and patient experience with sacral neuromodulation: results of a single center sample survey. J Urol 2011; 185(2): 588–592. doi: 10.1016/j.juro.2010.09.090.
52. Sutherland SE, Lavers A, Carlson A et al. Sacral nerve stimulation for voiding dysfunction: one institution’s 11-year experience. Neurourol Urodyn 2007; 26(1): 19–28.
53. Oerlemans DJ, Van Voskuilen AC, Marcelissen T et al. Is on-demand sacral neuromodulation in patients with OAB syndrome a feasible therapy regime? Neurourol Urodyn 2011; 30(8): 1493–1496. doi: 10.1002/nau.21070.
Labels
Paediatric urologist UrologyArticle was published in
Urological Journal
![Issue 3](https://www.prolekare.cz/media/cache/resolve/journal_issue/media/image_pdf/661ab63fb7dabdcf0385c914af5eb725.jpeg)
2015 Issue 3
Most read in this issue
- Selective estrogen receptor modulators and the management of male hypoandrogenism – a systematic analysis
- CURRENT MANAGEMENT OF ADULT NEUROGENIC BLADDER – A REVIEW
- “THE REZŪM™ SYSTEM” TECHNOLOGY IN THE TREATMENT OF BPH – MEDIUM-TERM CLINICAL OUTCOMES
- SEXUAL FUNCTION AFTER TRANSURETHRAL RESECTION OF THE PROSTATE